
==== Front
Nat Commun
Nat Commun
Nature Communications
2041-1723
Nature Publishing Group UK London

47387
10.1038/s41467-024-47387-1
Article
A modular and synthetic biosynthesis platform for de novo production of diverse halogenated tryptophan-derived molecules
Reed Kevin B. 1
http://orcid.org/0000-0002-6914-2504
Brooks Sierra M. 1
http://orcid.org/0000-0002-8742-6957
Wells Jordan 1
Blake Kristin J. 2
Zhao Minye 1
Placido Kira 1
http://orcid.org/0000-0001-7512-9157
d’Oelsnitz Simon 3
Trivedi Adit 1
Gadhiyar Shruti 1
http://orcid.org/0000-0002-8246-8605
Alper Hal S. halper@che.utexas.edu

13
1 https://ror.org/00hj54h04 grid.89336.37 0000 0004 1936 9924 McKetta Department of Chemical Engineering, The University of Texas at Austin, 200 E Dean Keeton St. Stop C0400, Austin, TX USA
2 https://ror.org/00hj54h04 grid.89336.37 0000 0004 1936 9924 Mass Spectrometry Facility, Department of Chemistry, The University of Texas at Austin, 105 E 24th Street, Austin, TX USA
3 https://ror.org/00hj54h04 grid.89336.37 0000 0004 1936 9924 Institute for Cellular and Molecular Biology, The University of Texas at Austin, 2500 Speedway Avenue, Austin, TX USA
12 4 2024
12 4 2024
2024
15 318822 7 2023
31 3 2024
© The Author(s) 2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Halogen-containing molecules are ubiquitous in modern society and present unique chemical possibilities. As a whole, de novo fermentation and synthetic pathway construction for these molecules remain relatively underexplored and could unlock molecules with exciting new applications in industries ranging from textiles to agrochemicals to pharmaceuticals. Here, we report a mix-and-match co-culture platform to de novo generate a large array of halogenated tryptophan derivatives in Escherichia coli from glucose. First, we engineer E. coli to produce between 300 and 700 mg/L of six different halogenated tryptophan precursors. Second, we harness the native promiscuity of multiple downstream enzymes to access unexplored regions of metabolism. Finally, through modular co-culture fermentations, we demonstrate a plug-and-play bioproduction platform, culminating in the generation of 26 distinct halogenated molecules produced de novo including precursors to prodrugs 4-chloro- and 4-bromo-kynurenine and new-to-nature halogenated beta carbolines.

De novo fermentation and synthetic pathway construction for halogen-containing molecules remain relatively underexplored. Here, the authors report a mix-and-match co-culture platform to de novo generate a large array of halogenated tryptophan derivatives in E. coli from glucose.

Subject terms

Biocatalysis
Metabolic engineering
Applied microbiology
Metabolic pathways
https://doi.org/10.13039/100000185 United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) 1000 Molecules Alper Hal S. https://doi.org/10.13039/100000001 National Science Foundation (NSF) GRFP Alper Hal S. issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The vast majority of biochemistry revolves around a finite number of elements on the periodic table. However, by coupling novel synthetic tools with the exploration of diverse microbial biochemical space, new pathways for the assimilation of more uncommon elements are emerging1–3. This expanded scope is moving metabolic engineering away from simply C–C, C–H, C–O, C–N, and C–S bonds and toward alternative chemical diversity, thus expanding the cellular chemical palette1,4,5. Among these alternative pathways of interest is the incorporation of halogen elements into microbial metabolism6–10. Halogenation chemistry has become rather ubiquitous in modern society with broad applications spanning pharmaceuticals11–14, agrochemicals15–17, and novel materials18–21. The critical incorporation of a halogen atom into compounds directly confers function as seen in examples such as the widely used polymer polyvinylchloride (PVC), the potent antibiotic chloramphenicol, and the flame retardant brominated polystyrene (BPS)22. Organic synthesis of halogenated compounds, while well-established and understood, is marred by highly toxic chemicals15, poor atom economy23, and limited stereo-/regio-selectivity24 that hinders targeted halogenation in complex molecules25. Furthermore, the requirement for enantiomerically pure end products often complicates separation and purification chemical synthesis of these compounds26. In contrast, biological synthesis routes can bypass many of these limitations and theoretically offer an effective and more environmentally friendly alternative for producing halogenated molecules at near ambient conditions.

In nature, halogenase enzymes generate precisely halogenated end products through a variety of reaction mechanisms27. To this end, an array of halogenases have been discovered and can be characterized into four main classes. These include, for example, members of the Fe(II)/alpha KG-dependent class of halogenases such as SyrB228, BesD and similar enzymes29, and late-stage halogenase WelO530. Other classes consist of the haloperoxidases and SAM-dependent halogenases17. Lastly, flavin-dependent halogenases constitute the final class, including RadH31 and Rdc232,33, late-stage halogenase MalA34, and, of particular interest for this study, the tryptophan halogenases such as RebH, PyrH, and Thal35–37. Among these enzymes, the tryptophan halogenases have been most extensively studied and engineered over the past few decades mainly in vitro and recently in vivo. More specifically, the varied regioselectivity of these enzymes offers halogenation across the 5-, 6-, or 7-positions of tryptophan with the 7-position most studied in large-scale efforts27. The first gram-scale production of 7-chloro-tryptophan from a tryptophan feed was demonstrated in vitro using cross-linked enzyme aggregates (CLEA’s)38. Recent efforts in the engineering of Corynebacterium glutamicum have demonstrated the first de novo and in vivo gram-scale production of 7-bromo-tryptophan39. These studies provide promise for expanding bio-based production to alternative hosts and halogenation positions within tryptophan at a scale relevant for commercially viable industrial production.

The combinatorial biochemistry afforded by linking halogenases with downstream enzymes can access a diverse array of halogenated compounds. Tryptophan itself serves as a gateway to a plethora of interesting natural products ranging from small molecules like indole, kynurenines, quinones, and tryptamines to larger molecules like violacein, strictosidine, and beta-carbolines40–43. To this end, several recent reports describe the in vivo production of tryptophan-derived, halogenated products. For example, halogenated kynurenine derivates, especially 4-chloro-kynurenine, were generated in Streptomyces coeliculr44, halogenated indolocarbazoles have been generated via combinatorial biosynthesis in S. albus45, and halogenated tryptophan derivatives for subsequent transition metal catalysis applications46. New-to-nature halogenated alkaloids47, indigoids48, and auxins49 have been created in planta. Additionally, halogenated quinolines and alkaloids were realized using yeast bioproduction platforms50,51. While these examples demonstrate advances in halogenated metabolism, they do not ubiquitously describe de novo microbial production of diverse halogenated tryptophan-derived compounds starting from simple sugar starting materials. This is an important consideration given the relatively expensive and low-water-soluble substrates often used in prior studies such as indole, tryptophan, or other halogenated precursor molecules, as well as need for de novo production in planta to rely on variable, seasonally-dependent crop yields51.

In this work, we harness halogenases and downstream pathways to generate industrially attractive halogenated molecules in a safe and effective manner through metabolic engineering and synthetic co-cultures. In doing so, we establish a co-culture system that uses mix-and-match technology to afford differential downstream halogenation type and position in a manner that enables combinatorial pathway assembly for diverse halogenated molecules. Specifically, we showcase high-level production of halogenated tryptophan analogs and a collection of strains/pathways that can enable subsequent transformation of these precursors into desirable compounds. Through a synthetic, modular co-culture system, 26 distinct halogenated molecules are generated de novo from glucose, including new-to-nature beta carbolines, prodrug precursors to 4-chloro- and 4-bromo-kynurenine, plant hormone precursors, and other pharmaceutically relevant precursor molecules including tryptamines and indoles. Taken together, this work unlocks halogenated biochemistry by uniting concepts from both combinatorial chemistry and synthetic biology.

Results

Enabling halogenated tryptophan production in an E. coli platform

While de novo production of halogenated tryptophan has been reported in C. glutamicum for 7-Br-tryptophan and detectable quantities of 7-Cl-tryptophan39,52, no studies have reported such production (for these particular halogenated forms or others) of close to gram-scale titers in E. coli. Initial efforts here evaluated the synthetic expression of halogenases and flavin reductase cofactor rebalance partners to enable production (Fig. 1). Specifically, production of halogenated tryptophan was evaluated using varying expression regimes for Th-Hal and flavin reductases Th-Fre and EcFre (Supplementary Fig. 1). These results reinforce previous literature that the native E. coli flavin reductase (EcFre) is not expressed highly enough to enable sufficient cofactor rebalance of FAD to FADH2 for high-level production of halo-tryptophan using tryptophan halogenases53. Specifically, only minimal halogenated tryptophan (e.g., 40 μM of 6-chloro-tryptophan from 1 mM of tryptophan fed) was produced without overexpression of a flavin reductase (Supplementary Fig. 1). Expression of a heterologous, more thermostable flavin reductase (Th-Fre) resulted in higher production over EcFre and the null strain, reinforcing the importance of optimizing the cofactor balance for the halogenase reaction as noted in prior studies36–38,46,47. This system also allowed for the optimization of copy number and promoters driving expression of Th-Hal as a model halogenase (Supplementary Note 1).Fig. 1 Selection of halogenases to acquire a panel of modified precursors.

A Reaction overview for tryptophan halogenases. 5-tryptophan-halogenases: PyrH, XsHal; 6-tryptophan-halogenases: Th-Hal, SttH, Thal; 7-tryptophan-halogenases: RebH, PrnA. B Experimental Design for halogenase panel. Strain sKR-160 containing respective halogenases and flavin reductase Th-Fre were supplied with 1 mM of tryptophan and production formation of respective halogenated tryptophan products (5-, 6-, 7-chloro-/bromo-tryptophan) was observed. C Panel of halogenases with calculated L-tryptophan conversion at varying temperatures: 25 °C, 30 °C, and 37 °C. Data are mean ± S.D.; n = 3 biological replicates. Source Data are provided as a Source Data file.

Establishing a panel of halo-tryptophan precursor production through halogenase selection

Using the expression platform above, we next evaluated the in vivo halogenation profile for a collection of halogenases comprised of at least two homologues capable of catalyzing each regioselective reaction at the 5, 6, or 7 positions of tryptophan including well-studied halogenases like Thal36, RebH37, PrnA54, and PyrH35 (Table 1). Tryptophan feeding assays were conducted (Fig. 1C) at varying temperatures to investigate the robustness of each enzyme and evaluation of chloro- and bromo-preferences (Supplementary Fig. 2).Table 1 List of halogenase enzymes used in this study

Halogenase	Organism of origin	Product formed	Halogenation position	
PyrH	Streptomyces rugosporus	5-halo-tryptophan	5	
XszenFHal (XsHal)	Xenorhabdus szentirmaii	5-halo-tryptophan	5	
Thal	Streptomyces albogriseolus	6-halo-tryptophan	6	
Th-Hal	Streptomyces violaceusniger	6-halo-tryptophan	6	
SttH	Streptomyces toxytricini	6-halo-tryptophan	6	
RebH	Lentzea aerocolonigenes	7-halo-tryptophan	7	
PrnA	Pseudomonas fluorescens	7-halo-tryptophan	7	

A few initial observations can be made from the halogenase panel. First, the halogenase XsHal displayed robust in vivo production of both 5-chloro- and 5-bromo-tryptophan precursors. At all temperatures, XsHal performs significantly better than its counterpart PyrH, an enzyme that has a very low reported melting temperature of around 30 °C55. Furthermore, XsHal is reported to have a 2-fold increase in catalytic efficiency over PyrH56 in vitro, yet exhibits multi-fold higher production in vivo at various temperatures. Second, the halogenase Thal shows the most consistent generation of both 6-chloro- and 6-bromo-tryptophan precursors at 30 °C, whereas Th-Hal, a reported halogenase from a thermophilic organism, shows the highest conversion of the tryptophan to 6-halo-tryptophan at 37 °C, with an evident preference for chloro- over bromo-addition. For the 7-tryptophan halogenases, RebH, which was previously used for other de novo halogenated molecule production in planta47, provided the most consistent conversion of tryptophan into 7-bromo- and 7-chloro-tryptophan precursors at 30 °C, whereas PrnA could be used as a reliable halogenase at higher temperatures. Lastly, halogenation was almost universally restricted at 25 °C with the exception of XsHal that enabled high turnover even at this suboptimal operating temperature. Based on these results, halogenases XsHal, Thal, and RebH were selected based on their superior conversion at 30 °C and ability to collectively access multiple halogenation sites for both chlorine and bromine on tryptophan.

Enabling de novo production of halo-tryptophan precursors through metabolic engineering

After characterizing the potential of E. coli to express functional halogenases and selecting a collection of functional enzymes, we employed a metabolic engineering approach to improve precursor availability and boost halo-tryptophan precursor production de novo. This effort focused broadly on the three goals of: (i) removal of degradation mechanisms, (ii) removal of feedback regulation, and (iii) overexpression of biosynthetic pathway enzymes (Fig. 2A).Fig. 2 Metabolic engineering in E. coli for L-tryptophan production.

A Genetic changes leading to high tryptophan production in E. coli BW25113 background and schematic of the tryptophan overproduction strategy for strain sKR-Trp4, the highest producer of tryptophan from glucose generated in this study. The outer loop within the bottom schematic of (A) represents the genome and relevant genomic modifications, including deletions of TrpR and TnaA and the integration of a precursor module containing SerA(fbr) and AroG(fbr) within the rbsAR locus. Glucose 6-P: glucose-6-phosphate; PP Pathway: pentose phosphate pathway; PEP: phosphoenolpyruvate; E4P: erythrose-4-phosphate; DAHP: 3-deoxy-D-arabino-heptulosonic acid 7-phosphate; DHQ: 3-dehydroquinate; DHS: 3-dehydroshikimate; S3P: shikimate-3-phosphate; EPSP: 5-enolpyruvylshikimate 3-phosphate; Ant: anthranilate; L-Trp: L-tryptophan; 3-PDG: 3-phospho-D-glycerate. B Tryptophan overproduction based on genetic modifications outlined in Table 2 and Supplementary Data 4. Each bar represents a biological triplicate for fermentations of 5 g/L glucose in minimal media after 24 h. Data are mean ± S.D.; n = 3 biological replicates. Source Data are provided as a Source Data file.

First, degradation was removed through targeting the tryptophanase (encoded by tnaA) for deletion to remove degradation into indoles57 and deletion of the TrpR transcriptional repressor that serves to regulate biosynthesis and transport58. Disruption of the trpR and tnaA genes did not immediately show appreciable accumulation of tryptophan in the cellular supernatant after 24 h (Fig. 2B). Second, removal of feedback inhibition and overexpression of biosynthetic enzymes in the aromatic amino acid pathway were incorporated into the strain and leveraged efforts of many reports to improve tryptophan overproduction59–61 including canonical targets including mutations in TrpE, AroG, and SerA to enable feedback resistance (fbr)62. A synthetic modularization of metabolism approach63 was conducted here consisting of a Precursor Module and a Tryptophan Biosynthesis Module. In this case, the Precursor Module consisted of overexpressions of AroG(fbr) and SerA(fbr) and the Tryptophan Biosynthesis Module consists of all the genes in the trp operon with peptide leader TrpL removed and the feedback-resistant mutant of TrpE, TrpE(fbr). Expression strength and copy numbers of these modules were optimized to obtain high levels of tryptophan overproduction (Fig. 2B). Table 2 outlines the collective metabolic modifications investigated in this study. The final strain modification strategy (Supplementary Discussion 1) resulted in a strain (E. coli sKR-Trp4) capable of producing over 200 mg/L of tryptophan after 24 h in minimal media containing only 5 g/L glucose in a 96-deep well plate (1 mL scale) (Fig. 2B).Table 2 Tryptophan overproduction strains with corresponding modifications constructed in this study

Strain name	Modifications	
sKR-Trp0	ΔTnaA::FRT	
sKR-Trp1	ΔTrpR::FRT and ΔTnaA::FRT	
sKR-Trp2	ΔTrpR::FRT, ΔTnaA::FRT, and pTrpOp-TrpE(fbr)DCBA	
sKR-Trp3	ΔTrpR::FRT, ΔTnaA::FRT, pTrpOp-TrpE(fbr)DCBA, and rbsAR::pJ23105-B32-SerA(fbr)-Pyibn-AroG(fbr)	
sKR-Trp4	ΔTrpR::FRT, ΔTnaA::FRT, pTrpOp-TrpE(fbr)DCBA, and rbsAR::pJ23105-B32-SerA(fbr)-B34-AroG(fbr)	
sKR-Trp5	ΔTrpR::FRT, ΔTnaA::FRT, ΔrbsAR::pJ23105-B32-SerA(fbr)-B34-AroG(fbr), and ΔtrpL::TP24-Ptac-TrpE(fbr)-TrpDCBA	

Using this high-tryptophan producing E. coli strain, it is possible to incorporate the above characterized halogenases to enable de novo production of halo-tryptophan precursors. To do so, the sKR-Trp4 strain was transformed with either XsHal, Thal, and RebH to generate three strains respectively (sKR-Trp4-XsHal, sKR-Trp4-Thal, and sKR-Trp4-RebH) (Fig. 3A). The resulting de novo titers of 0.3–0.7 g/L halogenated tryptophan for each corresponding halogenase fed with 40 g/L glucose and the corresponding halide salt are shown in Fig. 3B. These strains achieve a selectivity reaching as high as 96% for bromo-tryptophan even in the presence of competition for the halide salt with the residual chloride present in the growth media (Supplementary Fig. 3), consistent with previously reported selectivity in other organisms that use similar levels of bromide salt in the media39. Altogether, these findings showcase the highest titers of de novo varied halogenated tryptophan production at flask scale to date. It is important to note that these products are secreted and thus enable an easy access point for creating a modular diversification approach using a co-culture.Fig. 3 De novo production of halogenated tryptophan in E. coli.

A Schematic of final halogenated tryptophan overproduction strain, showing modular engineering. Hal: halogenase (XsHal, Thal, or RebH depending on the position of interest); Fl-Red: flavin reductase. B Reaction overviews of each introduced halogenase and corresponding production curves when fed with 40 g/L glucose for 72 h. Data are mean ± S.D.; n = 3 biological replicates. Source Data are provided as a Source Data file.

Initial halogen-product diversification through complementing promiscuous enzymes and feeding assays

Tryptophan is the most chemically complex proteogenic amino acid and can quickly be modified in many positions through even just single enzymatic steps to yield products with a diverse range of applications (Fig. 4A). To enable an exploration of this chemical space with halogenated compounds, enzymes were selected to target as many biologically accessible reaction centers of tryptophan as possible (Fig. 4, as determined by Transform MinER online module64). A total of 10 modifying enzymes (beyond the halogenases described earlier) were selected and evaluated for their ability to convert 500 μM of fed L-tryptophan to a corresponding downstream product. Of the explored set of enzymes, five of these enzymes (encoded by RgnTDC, iaaM, TnaA, KynA, and McbB) enabled conversion of all fed tryptophan (Supplementary Data 1). Molecules corresponding to the theoretical product 2a, 3a, 4a, 5a, and 6a were observed for each enzyme, respectively (Fig. 5A and Supplementary Figs. 4–41). Beyond this set, TsrM was observed to catalyze the reaction of tryptophan to 2-methyl-L-tryptophan (7a), though showed very minimal conversion of tryptophan fed and yielded low intensities on the LC-MS samples (Supplementary Figs. 42–46). Other enzymes did not convert any appreciable tryptophan under various fermentation and expression conditions after 48 h and the corresponding theoretical products 8a, 9a, 10a, and 11a were not observed (Fig. 3b; shown in white in the “Product Observed” column). These enzymes comprise either prenyltransferases, including CymD65, DmaW66, and etpPT67, and thus require a large pool of DMAPP to function well in vivo or are P450s, such as CYP79B2, with documented difficulties in soluble expression.Fig. 4 Establishing downstream pathways to access molecules from tryptophan.

A Overview of example molecules derived from tryptophan and the applications enabled by them. Molecules in the figure (in general order left to right) include Indole, Kynurenine, Kynurenic acid, Skatole, 3-methyl-2-indolic acid (MIA), Serotonin, Indole-3-acetic acid (auxin), Tryptamine, indole pyruvic acid, 1-acetyl-3-carboxy-beta-carboline, strictosidine, indigo, violacein, rebeccamycin, thaxtomin, vinblastine, cyclomarin A, ergoline, ergotamine, N,N-Dimethyltryptamine, Hapalindole A, melatonin, psilocybine, lysergic acid, physostigmine, pyrrolnitrin, and quinmerac. B Biologically available reaction centers of tryptophan investigated within this study accessible through a single enzymatic step. Note: This list is exemplary, not exhaustive. The modifications to the tryptophan scaffold are represented by colored reaction center dots, with colors corresponding to each reaction center displayed in (C). The green boxes in the product observed column represent the enzymes that converted tryptophan fed to the media into the expected product, as confirmed by LC-MS. C An overview of the halogen-product diversification strategy, utilizing promiscuity downstream enzymes to generate a wide range of halogenated tryptophan-derived products. D The chemical structure of the expected products are shown, with indications of observed and unobserved when 500 μM L-tryptophan was fed to the media.

Fig. 5 Evaluation of downstream promiscuity through feeding assays.

A Reaction overview for each downstream enzyme evaluated. B Each strain containing the corresponding downstream enzyme was fed 500 μM of each halogenated tryptophan analog. Each heat map square represents the formation (green) or lack of formation (white) of corresponding halogenated products from biological triplicates picked from individual colonies.

Nonetheless, a wide range of reactions are represented in this functional subset including a ring-opening, a ring-closing, cleavage of the amino acid group, and multiple modifications on the amino acid portion of tryptophan. Specifically, RgnTDC is a tryptophan decarboxylase (TDC) from the organism Ruminococcus gnavus, and catalyzes the formation of tryptamine, a physiologically important and highly relevant pharmaceutical precursor68,69. RgnTDC was previously characterized to be highly promiscuous towards many tryptophan derivatives, including halogenated ones70. iaaM is an enzyme involved in the production of auxin in plants, catalyzing the generation of indole-3-acetamide, and characterized to be promiscuous as well, although unknown at the outset of this study71. TnaA, E. coli’s native tryptophan indole lyase, catalyzes the production of indole, a precursor for many other molecules including indigo and other important tryptophan dimers72,73. KynA catalyzes a ring-opening reaction to generate N-formyl-L-kynurenine and comprises the first step in the kynurenine and quinone pathways, classes of molecules with many bioactive characteristics50,74,75. McbB, one of the genes that drives the biosynthesis of marinacarbolines, was found in the organism Marinactinospora thermotolerans SCSIO 00652, and catalyzes a Pictet-Spengler cyclization process76. Beta-carbolines in general have been shown to have very interesting chemical characteristics including optoelectronic properties, potential as anti-cancer agents, and many other bioactivities77–80. Specifically, the molecules formed through the Mcb pathway in Marinactinospora thermotolerans have been shown to have antimalarial, cytotoxic, and anti-inflammatory activities81,82. TsrM catalyzes the reaction to 2-methyl-L-tryptophan via a unique cobalamin-dependent radical SAM mechanism and is the first step towards the synthesis of the antibiotic thiostrepton A83–85. Thus, this set showcases a wide range of biochemical reactions with fundamentally valuable end products.

Next, we sought to evaluate and harness the promiscuity of these downstream enzymes toward fed halogenated substrates in an effort to create diverse halogenated products. As outlined in Fig. 5A, the six selected downstream enzymes were each evaluated for their ability to convert six different halogenated tryptophan variants in the background of a tnaA deletion strain to prevent any unwanted product degradation. The binary promiscuity observations for these 42 combinations (when considering tryptophan and all 6 halogenated variants) are provided in Fig. 5B, whereas structures are displayed in Supplementary Fig. 47. From these assays, all 6 potential molecule sets 2b, 2c, 2d, 2e, 2f, 2g and 3b, 3c, 3d, 3e, 3f, 3g were observed when RgnTDC and iaaM were expressed, respectively. RgnTDC and iaaM are thus remarkably promiscuous enzymes, evidenced by their ability to convert all positions of halogenated tryptophan, supported by similar reports in prior literature70,71. All possible molecules 4b, 4c, 4d, 4e, 4f, and 4g were also observed when TnaA was expressed, thus echoing similar trends of promiscuity reports from this enzyme53.

The remaining three enzymes were slightly less promiscuous, each making only 4 out of 6 possible halogenated downstream molecules. KynA was observed to readily convert 6-chloro (1d) and 6-bromo-tryptophan (1e) into 6-chloro-N-formyl-L-kyurenine (5d) and 6-bromo-N-formyl-L-kyurenine (5e), respectively, both precursors to prodrug 4-chloro- and 4-bromo-kynurenine44,86 (Fig. 6A). KynA also exhibits slight promiscuity for the 5-Cl and 5-Br positions (molecules 5b and 5c) but molecules 5f and 5g were not observed. McbB has a much more complicated reaction mechanism and restrictive active site bundled between two subunits87, yet was able to convert both the 5 and 7-position halo-tryptophan variants, molecules 1a, 1b, 1f, and 1g, to their corresponding carboline products, molecules 6b, 6c, 6f, and 6g, respectively with the 7-position produced at higher efficiency. Molecules 6d and 6e were not observed. Previous report have observed McbB’s ability to convert certain fluorine-modified tryptophans76, though this represents confirmation of larger halogen substituted tryptophans. The four observed molecules are new-to-nature chloro- and bromo-modified beta-carbolines, with the 7-position highlighted in Fig. 6B. Lastly, TsrM follows a similar promiscuity pattern as McbB, where molecules 7b, 7c, 7f, and 7g were observed, corresponding to promiscuity for the 5 and 7-positions, whereas molecules 7d and 7e were not observed, reflecting similar trends seen in vitro83. The potential for di-halogenation of these downstream molecules was also investigated and was not evident based on the resulting LC-MS data. While we were not able to obtain analytical standards for the majority of downstream halogenated molecules, we have provided estimated titers and conversions of fed substrates from the feeding assay based on consumption of fed substrate (Supplementary Data 1 and 2).Fig. 6 Confirmation of pharmaceutically relevant molecules through microbial fermentation.

A Confirmation of prodrug precursors 6-chloro-N-formyl-L-kynurenine (blue) and 6-bromo-N-formyl-L-kynurenine (orange). B Confirmation of new-to-nature molecules 7-chloro-1-acetyl-3-carboxy-β-carboline (blue) and 7-bromo-1-acetyl-3-carboxy-β-carboline (orange).

These feeding assays coupled with downstream reaction promiscuity demonstrates the chemical diversity possible from tryptophan, whereby the tryptophan scaffold can be chemically decorated in a variety of ways. In general, we observed that promiscuity was related to the distance of the halogen from the specific reaction center in addition to the simplicity of the reaction mechanism. For example, RgnTDC and iaaM are remarkably promiscuous and both catalyze reactions near the α-carbon. TnaA is also highly promiscuous and catalyzes a simple cleavage reaction of the β-carbon bond from the indole side group. KynA, TsrM, and McbB on the other hand catalyze more complex reactions such as a complex ring opening, a methylation of the C-2 carbon, and ring closing reactions, respectively, within or very close to the indole side group. To further confirm our empirical observations, we pursued a computational investigation to determine relative binding energies between iaaM and McbB for tryptophan and halo-tryptophan precursors (Supplementary Discussion 2). General promiscuity trends were supported wherein iaaM has a larger binding pocket that can accommodate all variations of tryptophan and McbB’s preference for 7-halo-tryptophan over the other positions is highly evident from the conformational change of a tyrosine group in the active site that especially occludes the 6-halo- position (Supplementary Table 1 and Supplementary Figs. 48–51).

De novo production of halogenated products using synthetic, modular co-cultures

To enable true de novo production of rapidly diversified halogenated molecules, we sought to utilize a co-culture approach (Fig. 7), which represents a break from the convention of most previous downstream diversification of halogenated tryptophan works focused on combined pathway engineering within single cells46,47,71. Given that the halogenated tryptophan molecule is secreted from the cell, this point represents a natural break in metabolic pathways. Thus, combining a halogenated tryptophan overproduction strain with a downstream conversion strain can enable de novo production of an array of halogenated compounds. Moreover, we hypothesized that this co-culture approach was necessary as a consolidated bioprocessing approach (wherein halogenase and downstream enzyme are co-localized) would lead to high competition for the intracellular tryptophan pool by both competing pathways and result in more un-halogenated products. Similar approaches have been used to reduce metabolic burden and generate a variety of products downstream of tryptophan, such as tryptamine and indigo88,89. Thus, one cell can act to primarily produce halogenated tryptophan whereas the other cell can specialize on the downstream conversion of halogenated tryptophan.Fig. 7 Modular one-pot de novo co-culture reactions enable halogenated product diversity.

Schematic of the modular one-pot de novo co-culture reactions to enable halogenated product diversity. One strain converts glucose into 5-, 6-, or 7-halogenated tryptophan. The second strain converts the halogenated tryptophan into a halogenated downstream product which is secreted into the media. Boxes with both Br and Cl icons refer to downstream products for which both brominated and chlorinated versions have been detected using each respective downstream enzyme. Boxes without Br and Cl refer to downstream products which were not detected when attempting the specified co-culture.

To determine the effectiveness of the modular co-culture reactions, we compared the production of the non-halogenated downstream molecule using the wild-type tryptophan pool to that of the non-halogenated product formed during the co-culture reactions with both the halo-trp overproduction strain and downstream conversion strain. We evaluated this strategy for molecules where standards were available (5-chloro- and 5-bromo-tryptamine). As compared to a blank plasmid control, it was discovered that all the halo-tryptophan was readily converted into the equivalent halo-tryptamine molecule with a minimal increase in amount of the non-halogenated tryptamine product (Supplementary Figs. 52 and 53). Thus, the spatial separation effectively enables the generation of primarily the halogenated version. At the same time, we confirm de novo production of 36 mg/L of 5-chloro-tryptamine and 52 mg/L of 5-bromo-tryptamine at the 1 mL scale.

By deploying these modular, one-pot de novo co-culture reactions, we have confirmed the production of 26 distinct halogenated molecules from a glucose feedstock (Fig. 8). As expected, the de novo production results echo the feeding assays, where certain positions and enzymes are more promiscuous than others (Supplementary Figs. 54–84). TsrM was excluded from these experiments due to the low conversion of the native tryptophan substrate during the feeding assays. These de novo production schemes unlocked new access to synthesis from glucose in a microbial host of many of these products at the time the study was completed, highlighted with a circle (Fig. 8). Among these products include new-to-nature molecules, highlighted with a star, such as precursors to kynurenine prodrugs and the 5-chloro-, 5-bromo-, 7-chloro-, and 7-bromo-1-acetytl-3-carboxy-β-carboline molecules that provide pathways to halogenated molecules that can serve as anti-inflammatory agents. While we were not able to obtain analytical standards for the majority of these products to enable full quantification, we have provided estimated titers of all products successfully produced via this co-culture format based on relative LCMS abundance areas and feeding assay estimated titers (Supplementary Data 2). These estimated titers have been benchmarked against exact titers for 5-Cl-Tryptamine and 5-Br-Tryptamine, quantified via use of commercially available analytical standards (Supplementary Table 2). The estimated 5-Br-Tryptamine titer falls within 5% of the exact titer, while the estimated 5-Cl-Tryptamine titer exceeds the exact titer by ~50%. This indicates that the estimation accuracy likely varies with each compound. However, these estimates provide a general sense of titer scale (e.g., 1 mg/L vs 10 mg/L vs 100 mg/L), providing our best approximation in the absence of available reference standards for the majority of downstream halogenated compounds produced in this study. To provide clarity on the purity of compounds produced via co-culture, we have also provided estimated yields based on produced downstream molecule divided by total product, tryptophan and/or halo-tryptophan formed in the co-culture reaction (equal to product formed + residual tryptophan/halo-tryptophan; Supplementary Data 3).Fig. 8 De novo production of a wide range of tryptophan-derived halogenated products through modular one-pot co-cultures.

A Production of chloro-specific products, where each heat map square represents the formation (blue) or lack of formation (white) of corresponding halogenated products from biological triplicates picked from individual colonies. New-to-nature molecules are designated with a black star and products produced via de novo microbial synthesis for the first time are designated with a black circle. B production of bromo-specific products, where each heat map square represents the formation (orange) or lack of formation (white) of corresponding halogenated products from biological triplicates picked from individual colonies. New-to-nature molecules are designated with a black star and products produced by microbial synthesis are designated with a black circle. C Confirmation of de novo production of 6-chloro-N-formyl-L-kynurenine (5d), 6-bromo-N-formyl-L-kynurenine (5e), 7-chloro-1-acetyl-3-carboxy-β-carboline (6f), 7-bromo-1-acetyl-3-carboxy-β-carboline (6g), respectively, via LC-MS.

Discussion

Bioproduction offers a green solution for the generation of a diverse range of functional products. Herein, we have engineered E. coli as a microbial platform to convert glucose into a wide diversity of halogenated tryptophan derivatives. We showcase that through various engineering approaches, we can rapidly develop platform strains capable of producing six different halogenated tryptophan precursors de novo from glucose at high milligram-per-liter scales in flasks. This platform opens the door to many more applications and pushes the envelope towards reaching commercial viability for de novo biosynthesis of diverse halogenated molecules. By then investigating native promiscuity of six disparate downstream reactions in vivo, we show that many enzymes are amenable to further convert halogenated tryptophan precursors into a variety of halogenated downstream products in vivo, largely consistent with previous reports of promiscuity48,50,53,70,71. Lastly, we show that the halogenated tryptophan overproduction strains and strains equipped with downstream enzymes can be combined in a modular co-culture fashion to generate over 26 distinct halogenated molecules including 15 first-time de novo biosynthesized, of which 6 are entirely new-to-nature products. Future investigation of promiscuity for the pathway enzymes is warranted, where quantification via in vitro reactions could enable a better understanding of each enzyme’s ability to turnover halogenated tryptophan variants. Additionally, pursuits to engineer and evolve native selectivity in favor of the halogenated variant of interest could prove fruitful, similar to the enzymes that have already evolved in nature, such as Tar13, that are more specific for halogenated tryptophan than for tryptophan44. Taken together, this platform demonstrates a synthetic bio-combinatorial chemistry approach to yield de novo production of halogenated compounds of relevance to a variety of industrial sectors.

Methods

Chemicals and materials

L-tryptophan, indole, 5-chloroindole, 6-chloroindole, 7-chloroindole, 5-bromoindole, 6-bromoindole and 7-bromoindole were purchased from Sigma-Aldrich. 5-chloro-L-tryptophan, 5-bromo-L-tryptophan, 6-chloro-L-tryptophan, 7-chloro-L-tryptophan, and 7-bromo-L-tryptophan were purchased from Advanced Chemblocks, Inc. 6-bromo-L-tryptophan was purchased from Santa Cruz Biotechnology. D/L versions were purchased from the same vendor. M9, Minimal Salts, 5X was purchased through Sigma-Aldrich.

Strains, plasmids, and transformations

Escherichia coli strain BW25113 with deletions of tnaA or trpR were obtained from E. coli Genetic Resources at Yale CGSC, The Coli Genetic Stock Center. Bacterial genomic DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega). Lamba Red Recombination was used for integration of relevant cassettes (Upstream Module) which has been well-documented elsewhere90. pHal, with pBR322 origin and TacI promoter was used for all final experiments. Plasmids were assembled using either Gibson’s method, ligation, or a modified Golden Gate cloning method to produce plasmids91. Plasmids, primers, ORFs, and other genetic elements are listed in Supplementary Tables 3 and 4 as well as Supplementary Data 4. Various PCR products were then inserted into this plasmid under control of the strong Ptac promoter for overexpression in E. coli. These plasmids are referred to as pHal throughout this work. The inserts were PCR amplified using Q5 Hot Start High-Fidelity DNA Polymerase (NEB). Cells were then electroporated and recovered in 1 mL SOC at 37 °C for 1 h. A small portion was plated on LB+Amp+Chl plates to check for transformation efficiency, while the rest was moved to LB+Amp+Chl to grow overnight. Cultures were then freezer stocked and added to screening plates the next day.

Halogenase and flavin reductase expression

Strains with specified plasmids were typically grown in LB with appropriate antibiotics overnight. The next day, cultures were diluted back to an OD of 0.1 and allowed to grow for 2 h at 37 °C until OD reached 0.7–0.9. 1 mM IPTG was then added and cultures were grown at 30 °C for 2 h to induce expression of halogenase and flavin reductase. Cultures were spun down and media was replaced with M9 salts, 5 g/L glucose, and 1 g/L casamino acids with appropriate antibiotics, 1 mM IPTG, and 1 mM L-tryptophan. Suspension cultures were grown in Fisherbrand™ 96-Well DeepWell™ Polypropylene Microplates and incubated using an Infors HT Multitron Pro with 1000 rpm shaking.

Halogenase panel experimental conditions

Strains containing pHal-ThFre-Hal (various halogenases) were grown in LB with Amp (100 µg/mL) overnight. The next day, cultures were diluted back to an OD of 0.1 and allowed to grow for 2 h at 37 °C until OD reached 0.7–0.9. 1 mM IPTG was then added and cultures were grown at 30 °C for 2 h to induce expression of halogenase and flavin reductase. Cultures were spun down and media was replaced with M9G + CAA with appropriate antibiotics, 1 mM IPTG, and 1 mM L-tryptophan. Suspension cultures were grown in Fisherbrand™ 96-Well DeepWell™ Polypropylene Microplates and incubated using an Infors HT Multitron Pro with 1000 rpm shaking.

De novo production of halogenated tryptophan in E. coli

Strains containing specified modifications were grown up in LB with any necessary antibiotics overnight at 30 °C. The next day, these strains were diluted back 100-fold to OD ~ 0.1 and allowed to grow to OD 0.7–0.9 in 25 mL LB media at 37 °C in a 250 mL shake flask. Cultures were then induced with 1 mM IPTG and allowed to grow for 2 h at 30 °C. Cultures were then spun down at 3000 × g for 10 min in Falcon tubes to remove LB media and were replaced with 25 mL of M9G media (M9 salts, 40 g/L glucose) and placed in a 250 mL shake flask. These were then allowed to grow up for 72 h with timepoints taken every 12 h to be analyzed on HPLC.

Downstream promiscuity feeding assays

Strains containing corresponding downstream enzymes were grown up in LB+Chl (34 µg/mL) overnight. Strains were then inoculated at OD ~ 0.1 in M9G + CAA+Chl and allowed to grow for 2 h in which 1 mM IPTG and 500 μM of corresponding halogenated tryptophan analogs were added to the media. Downstream products were then confirmed via LC-MS.

Downstream promiscuity docking studies

The Rosetta software suite is a platform for the computational modeling of protein structures. PyRosetta, a Python binding for Rosetta92, was utilized to compare the structures of iaaM and McbB (Protein Data Bank accession codes of 4iv9 and 3 × 27, respectively), as these crystal structures are the only structures in this study to contain bound tryptophan. An ensemble of conformations in “.mol” format were generated for 5-chloro-, 5-bromo-, 6-chloro-, 6-bromo-, 7-chloro-, and 7-bromo-tryptophan using the OpenBabel chemical toolbox. These were then converted into a “.param” file and several “.pdb” files for use with PyRosetta. Each halogenated tryptophan was aligned to the native tryptophan binding mode in each enzyme crystal structure, resulting in 14 complexes including the original complex. Each complex was minimized into Rosetta’s energy scoring system using the “ref2015_cart” scorefunction and FastRelax. Finally, each complex was analyzed using the InterfaceAnalyzerMover to determine an overall binding energy or ΔΔG. All code used to generate the structures and binding scores can be found at https://github.com/jordantwells42/downstream-docking.

De novo co-culture production of halogenated tryptophan derivatives in E. coli

Strains containing specified modifications were grown up in LB with any necessary antibiotics overnight at 30 °C. The next day, these strains were diluted back 100-fold to OD ~ 0.1 and allowed to grow to OD 0.7–0.9 in 1 mL LB media at 37 °C. Cultures were then induced with 1 mM IPTG and allowed to grow for 2 h at 30 °C. Cultures were then spun down at 3000 × g for 10 min to remove LB media and were replaced with 500 µL of M9G media with micronutrients (M9 salts, 40 g/L glucose, 1X micronutrient solution), then combined together in a single reaction of 1 mL total volume. These were then allowed to incubate for 48 h, where the supernatants were spun down and analyzed on HPLC.

Quantification of products

Cultures were typically grown at 30 °C in a shaking incubator at 1000 rpm for specified amounts of time (0-48 h). After specified amounts of time, OD600 was measured using a Tecan plate reader as necessary. Cultures were then centrifuged at 3000 × g for 10 min to pellet the cells, and the supernatant was removed for further analysis. Metabolite quantification was performed on HPLC or LC-MS using authentic standards, depending on availability. Supernatants were then submitted for LC-MS analysis to confirm the presence of the expected downstream products for each reaction or compared to authentic standards on HPLC for the case of indole analogs, which had difficulty fragmenting on the MS, even at high concentrations of an authentic standard. Quantification was performed on a Dionex UltiMate 3000 (Thermo) equipped with an LS Eclipse Plus C18 column (3.0 × 150 mm, 3.5 µm; Agilent). The mobile phase for tryptophan and halogenated tryptophan analysis consisted of 1% (v/v) acetic acid in water or acetonitrile. Detection was performed at 280 nm with a flow rate of 0.3 mL min−1 and a column temperature of 30 °C. Data processing was performed using Chromeleon software. Calibration standards were prepared for tryptophan and halogenated tryptophan. Downstream molecules were detected on an LC-MS. Sample supernatants were loaded directed into the instrument without additional preparation. All measurements were performed in biological triplicate with representative spectra displayed in the supplemental information. For LC/MS analysis, the samples were analyzed using an Agilent 6546 A Q-TOF interfaced with an Agilent 1260 Infinity II liquid chromatography system (G7112B) and an Agilent Dual Jet Stream electrospray ionization (ESI) source (G1958-65271). The mass spectrometry conditions were as follows: autosampler temperature 7 °C; column temperature 30 °C; electrospray ionization in positive mode; capillary voltage 3500 V; nozzle voltage 2000 V; fragmentor voltage 80 V; nitrogen drying gas temperature 350 °C; nitrogen drying gas flow rate 10 L/min; sheath gas temperature 350 °C; sheath gas flow rate 11 L/min; nebulizer pressure 60 psi; mass range 50–1000 m/z. LC separations were achieved on an Agilent Rapid Resolution HD ZORBAX Eclipse Plus C18 column (P.N. 959757-902: 50 × 2.1 mm, 1.8 micron particle size) preceded by an Agilent ZORBAX Eclipse Plus C18 narrow bore guard column (P.N. 821125-936: 12.5 × 2.1 mm, 5 micron particle size). The LC conditions were as follows: solvent A was Water with 0.1% formic acid; solvent B was Acetonitrile; flow rate 0.4 mL/min; gradient ramp held 5% B for 2 min, ramped to 20% B from 2 to 5 min, ramped to 95% B from 5 to 12 min, held at 95% B until 16 min, then re-equilibrated at 5% B from 16.1 to 20 min. LC/MS data were collected using Agilent MassHunter Workstation LC/MS Data Acquisition for 6500 series Q-TOF (Version 10.1) and analyzed using Agilent MassHunter Workstation Qualitative Analysis (Version 10.0) software. All m/z values and spectra were calculated and collected based on the expected structures of the respective compounds of interest using MassHunter’s internal search function.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Reporting Summary

Source data

Source Data

Supplementary information

The online version contains supplementary material available at 10.1038/s41467-024-47387-1.

Acknowledgements

This work developed in part with funding through a subcontract from Zymergen under the Defense Advanced Research Projects Agency’s (DARPA) Living Foundries: 1000 Molecule program. The views, opinions, and/or findings expressed are those of the author and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. Sequencing was conducted at the Genomic Sequencing and Analysis Facility (RRID no. SCR_021713). LC-MS and other analytical characterizations were conducted at the UT Mass Spectrometry Facility. K.B.R. and S.M.B. acknowledge a National Science Foundation (NSF) Graduate Fellowship.

Author contributions

H.S.A. and K.B.R. conceived the project idea. K.B.R., H.S.A., and S.M.B. designed and directed the research. K.B.R. and H.S.A. wrote the manuscript. K.B.R., H.S.A., and S.M.B. revised the manuscript. K.B.R. and S.M.B. carried out experiments and interpreted the results under the guidance and direction of H.S.A. J.W. performed docking simulations. K.J.B. performed LC/MS analysis and compiled results. M.Z., K.P., S.D., A.T., and S.G. contributed to gene construction, culturing, and analysis. All authors reviewed the final version of the manuscript.

Peer review

Peer review information

Nature Communications thanks anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Data availability

Data supporting the findings of this work are available within the paper and its Supplementary Information file. A reporting summary for this Article is available as a Supplementary Information file. Source data are provided with this paper.

Code availability

All code used in this study can be found at Github [https://github.com/jordantwells42/downstream-docking].

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Kevin B. Reed, Sierra M. Brooks.
==== Refs
References

1. Reed KB Alper HS Expanding beyond canonical metabolism: interfacing alternative elements, synthetic biology, and metabolic engineering Synth. Syst. Biotechnol. 2018 3 20 33 10.1016/j.synbio.2017.12.002 29911196
2. Chellan P Sadler PJ The elements of life and medicines Philos. Trans. A Math. Phys. Eng. Sci. 2015 373 20140182 25666066
3. Wackett LP Dodge AG Ellis LBM Microbial genomics and the periodic table Appl. Environ. Microbiol. 2004 70 647 655 10.1128/AEM.70.2.647-655.2004 14766537
4. Goss RJ Shankar S Fayad AA The generation of “unNatural” products: synthetic biology meets synthetic chemistry Nat. Prod. Rep. 2012 29 870 889 10.1039/c2np00001f 22744619
5. Jackie Tsoi C Khosla C Combinatorial biosynthesis of ‘unnatural’ natural products: the polyketide example Chem. Biol. 1995 2 355 362 10.1016/1074-5521(95)90214-7 9383437
6. Walker MC Natural and engineered biosynthesis of fluorinated natural products Chem. Soc. Rev. 2014 43 6527 6536 10.1039/C4CS00027G 24776946
7. Latham, J., Brandenburger, E., Shepherd, S. A., Menon, B. R. K. & Micklefield, J. Development of halogenase enzymes for use in synthesis. Chem. Rev. 10.1021/acs.chemrev.7b00032 (2017).
8. van Pee K-H Biosynthesis of halogenated metabolites by bacteria Annu. Rev. Microbiol. 1996 50 375 399 10.1146/annurev.micro.50.1.375 8905085
9. Bradley, S. A., Zhang, J. & Jensen, M. K. Deploying microbial synthesis for halogenating and diversifying medicinal alkaloid scaffolds. Front. Bioeng. Biotechnol. 8, 594126 (2020).
10. Gkotsi, D. S. et al. A marine viral halogenase that iodinates diverse substrates. Nat. Chem. 10.1038/s41557-019-0349-z (2019).
11. Ayala M Segovia L Torres E Halogenases: a biotechnological alternative for the synthesis of halogenated pharmaceuticals Mini-Rev. Med. Chem. 2016 16 1100 1111 10.2174/1389557516666160623100619 27337971
12. Heidrich, J., Sperl, L. E. & Boeckler, F. M. Embracing the diversity of halogen bonding motifs in fragment-based drug discovery—construction of a diversity-optimized halogen-enriched fragment library. Front. Chem. 7, 9 (2019).
13. Benedetto Tiz D New halogen-containing drugs approved by FDA in 2021: an overview on their syntheses and pharmaceutical use Molecules 2022 27 1643 10.3390/molecules27051643 35268744
14. Hernandes MZ Cavalcanti SMT Moreira DRM de Azevedo Junior WF Leite ACL Halogen atoms in the modern medicinal chemistry: hints for the drug design Curr. Drug Targets 2010 11 303 314 10.2174/138945010790711996 20210755
15. Jeschke P Manufacturing approaches of new halogenated agrochemicals Eur. J. Org. Chem. 2022 2022 e202101513 10.1002/ejoc.202101513
16. Jeschke P The unique role of halogen substituents in the design of modern agrochemicals Pest Manag. Sci. 2010 66 10 27 10.1002/ps.1829 19701961
17. Büchler J Papadopoulou A Buller R Recent advances in flavin-dependent halogenase biocatalysis: sourcing, engineering, and application Catalysts 2019 9 1030 10.3390/catal9121030
18. Saccone M Catalano L Halogen bonding beyond crystals in materials science J. Phys. Chem. B 2019 123 9281 9290 10.1021/acs.jpcb.9b07035 31525288
19. Kampes R Halogen bonding in polymer science: towards new smart materials Chem. Sci. 2021 12 9275 9286 10.1039/D1SC02608A 34349897
20. Ye, W. et al. Halogen-based functionalized chemistry engineering for high-performance supercapacitors. Chin. Chem. Lett.10.1016/j.cclet.2022.02.004 (2022)
21. Biswas S Das A Recent developments in polymeric assemblies and functional materials by halogen bonding ChemNanoMat 2021 7 748 772 10.1002/cnma.202100161
22. Cavallo G The halogen bond Chem. Rev. 2016 116 2478 2601 10.1021/acs.chemrev.5b00484 26812185
23. Podgoršek A Zupan M Iskra J Oxidative halogenation with “green” oxidants: oxygen and hydrogen peroxide Angew. Chem. Int. Ed. 2009 48 8424 8450 10.1002/anie.200901223
24. Neumann CS Fujimori DG Walsh CT Halogenation strategies in natural product biosynthesis Chem. Biol. 2008 15 99 109 10.1016/j.chembiol.2008.01.006 18291314
25. Zaragoza Dörwald, F. et al. Electrophilic halogenation of arenes. in Side Reactions in Organic Synthesis II 121–160 (John Wiley & Sons, Ltd, 2014).
26. Brown S O’Connor SE Halogenase engineering for the generation of new natural product analogues ChemBioChem 2015 16 2129 2135 10.1002/cbic.201500338 26256103
27. Agarwal V Enzymatic halogenation and dehalogenation reactions: pervasive and mechanistically diverse Chem. Rev. 2017 117 5619 5674 10.1021/acs.chemrev.6b00571 28106994
28. Vaillancourt FH Yin J Walsh CT SyrB2 in syringomycin E biosynthesis is a nonheme FeII α-ketoglutarate- and O2-dependent halogenase Proc. Natl Acad. Sci. USA 2005 102 10111 10116 10.1073/pnas.0504412102 16002467
29. Neugebauer ME A family of radical halogenases for the engineering of amino-acid-based products Nat. Chem. Biol. 2019 15 1009 1016 10.1038/s41589-019-0355-x 31548692
30. Zhu Q Hillwig ML Doi Y Liu X Aliphatic halogenase enables late-stage C-H functionalization: selective synthesis of a brominated fischerindole alkaloid with enhanced antibacterial activity Chembiochem 2016 17 466 470 10.1002/cbic.201500674 26749394
31. Menon, B. R. K. et al. RadH: a versatile halogenase for integration into synthetic pathways. Angew. Chem. Int. Ed. 10.1002/anie.201706342 (2017).
32. Zeng J Zhan J A novel fungal flavin-dependent halogenase for natural product biosynthesis ChemBioChem 2010 11 2119 2123 10.1002/cbic.201000439 20827793
33. Wang S Metabolic engineering of Escherichia coli for the biosynthesis of various phenylpropanoid derivatives Metab. Eng. 2015 29 153 159 10.1016/j.ymben.2015.03.011 25819309
34. Fraley AE Function and structure of MalA/MalA′, iterative halogenases for late-stage C–H functionalization of indole alkaloids J. Am. Chem. Soc. 2017 139 12060 12068 10.1021/jacs.7b06773 28777910
35. Zehner S A regioselective tryptophan 5-halogenase is involved in pyrroindomycin biosynthesis in Streptomyces rugosporus LL-42D005 Chem. Biol. 2005 12 445 452 10.1016/j.chembiol.2005.02.005 15850981
36. Seibold C A flavin-dependent tryptophan 6-halogenase and its use in modification of pyrrolnitrin biosynthesis Biocatal. Biotransformation 2006 24 401 408 10.1080/10242420601033738
37. Yeh E Garneau S Walsh CT Robust in vitro activity of RebF and RebH, a two-component reductase/halogenase, generating 7-chlorotryptophan during rebeccamycin biosynthesis Proc. Natl Acad. Sci. USA 2005 102 3960 3965 10.1073/pnas.0500755102 15743914
38. Frese M Sewald N Enzymatic halogenation of tryptophan on a gram scale Angew. Chem. Int. Ed. 2015 54 298 301 10.1002/anie.201408561
39. Veldmann, K. H. et al. Bromination of L-tryptophan in a fermentative process with Corynebacterium glutamicum. Front. Bioeng. Biotechnol. 7, 219 (2019).
40. Almeida MC Resende DISP da Costa PM Pinto MMM Sousa E Tryptophan derived natural marine alkaloids and synthetic derivatives as promising antimicrobial agents Eur. J. Med. Chem. 2021 209 112945 10.1016/j.ejmech.2020.112945 33153766
41. Roszkowski P Variety of natural products derived from tryptophan and stereoselective synthesis of tetrahydro-β-carboline derivatives of pharmacological importance Int. Congr. Ser. 2007 1304 46 59 10.1016/j.ics.2007.07.003
42. Alkhalaf LM Ryan KS Biosynthetic manipulation of tryptophan in bacteria: pathways and mechanisms Chem. Biol. 2015 22 317 328 10.1016/j.chembiol.2015.02.005 25794436
43. Lenz C Sherwood A Kargbo R Hoffmeister D Taking different roads: l-tryptophan as the origin of psilocybe natural products ChemPlusChem 2021 86 28 35 10.1002/cplu.202000581 33237633
44. Luhavaya H Sigrist R Chekan JR McKinnie SMK Moore BS Biosynthesis of l-4-chlorokynurenine, an antidepressant prodrug and a non-proteinogenic amino acid found in lipopeptide antibiotics Angew. Chem. Int. Ed. 2019 58 8394 8399 10.1002/anie.201901571
45. Sánchez C Combinatorial biosynthesis of antitumor indolocarbazole compounds Proc. Natl Acad. Sci. USA 2005 102 461 466 10.1073/pnas.0407809102 15625109
46. Sharma SV Living GenoChemetics by hyphenating synthetic biology and synthetic chemistry in vivo Nat. Commun. 2017 8 229 10.1038/s41467-017-00194-3 28794415
47. Runguphan W Qu X O’Connor SE Integrating carbon-halogen bond formation into medicinal plant metabolism Nature 2010 468 461 464 10.1038/nature09524 21048708
48. Fräbel S Engineering of new-to-nature halogenated indigo precursors in plants Metab. Eng. 2018 46 20 27 10.1016/j.ymben.2018.02.003 29466700
49. Davis K Nicotiana benthamiana as a transient expression host to produce auxin analogs Front. Plant Sci. 2020 11 581675 10.3389/fpls.2020.581675 33329644
50. Torrens-Spence MP Liu C-T Weng J-K Engineering new branches of the kynurenine pathway to produce oxo-(2-aminophenyl) and quinoline scaffolds in yeast ACS Synth. Biol. 2019 8 2735 2745 10.1021/acssynbio.9b00368 31714755
51. Li, Y. et al. Complete biosynthesis of noscapine and halogenated alkaloids in yeast. Proc. Natl Acad. Sci. USA.10.1073/pnas.1721469115 (2018).
52. Veldmann KH Minges H Sewald N Lee J-H Wendisch VF Metabolic engineering of Corynebacterium glutamicum for the fermentative production of halogenated tryptophan J. Biotechnol. 2019 291 7 16 10.1016/j.jbiotec.2018.12.008 30579891
53. Lee, J. et al. Production of Tyrian purple indigoid dye from tryptophan in Escherichia coli. Nat. Chem. Biol.10.1038/s41589-020-00684-4 (2020).
54. Dong C Tryptophan 7-halogenase (PrnA) structure suggests a mechanism for regioselective chlorination Science 2005 309 2216 2219 10.1126/science.1116510 16195462
55. Menon BRK Structure and biocatalytic scope of thermophilic flavin-dependent halogenase and flavin reductase enzymes Org. Biomol. Chem. 2016 14 9354 9361 10.1039/C6OB01861K 27714222
56. Domergue J XszenFHal, a novel tryptophan 5-halogenase from Xenorhabdus szentirmaii AMB Expr. 2019 9 175 10.1186/s13568-019-0898-y
57. Rodriguez A Engineering Escherichia coli to overproduce aromatic amino acids and derived compounds Microb. Cell Fact. 2014 13 126 25200799
58. Gunsalus, R.P., Yanofsky, C. Nucleotide sequence and expression of Escherichia coli trpR, the structural gene for the trp aporepressor. 10.1073/pnas.77.12.7117 (1980).
59. Gu P The improved l-tryptophan production in recombinant Escherichia coli by expressing the polyhydroxybutyrate synthesis pathway Appl. Microbiol. Biotechnol. 2013 97 4121 4127 10.1007/s00253-012-4665-0 23321909
60. Dodge TC Gerstner JM Optimization of the glucose feed rate profile for the production of tryptophan from recombinant E coli J. Chem. Technol. Biotechnol. 2002 77 1238 1245 10.1002/jctb.698
61. Chen L Zeng A-P Rational design and metabolic analysis of Escherichia coli for effective production of L-tryptophan at high concentration Appl. Microbiol. Biotechnol. 2017 101 559 568 10.1007/s00253-016-7772-5 27599980
62. Liu L Bilal M Luo H Zhao Y Iqbal HMN Metabolic engineering and fermentation process strategies for L-tryptophan production by Escherichia coli Processes 2019 7 213 10.3390/pr7040213
63. Reed KB Alper HS Modular biocatalysis for polyamines Nat. Catal. 2021 4 449 450 10.1038/s41929-021-00636-8
64. Tyzack JD Ribeiro AJM Borkakoti N Thornton JM Exploring chemical biosynthetic design space with transform-MinER ACS Synth. Biol. 2019 8 2494 2506 10.1021/acssynbio.9b00105 31647630
65. Schultz AW Lewis CA Luzung MR Baran PS Moore BS Functional characterization of the cyclomarin/cyclomarazine prenyltransferase CymD directs the biosynthesis of unnatural cyclic peptides J. Nat. Prod. 2010 73 373 377 10.1021/np9006876 20055491
66. Nielsen CA The important ergot alkaloid intermediate chanoclavine-I produced in the yeast Saccharomyces cerevisiae by the combined action of EasC and EasE from Aspergillus japonicus Microb. Cell Fact. 2014 13 95 10.1186/s12934-014-0095-2 25112180
67. Kremer A Westrich L Li S-M A 7-dimethylallyltryptophan synthase from Aspergillus fumigatus: overproduction, purification and biochemical characterization Microbiology 2007 153 3409 3416 10.1099/mic.0.2007/009019-0 17906140
68. Tittarelli R Mannocchi G Pantano F Romolo FS Recreational use, analysis and toxicity of tryptamines Curr. Neuropharmacol. 2015 13 26 46 10.2174/1570159X13666141210222409 26074742
69. Ehrenworth AM Peralta-Yahya P Accelerating the semisynthesis of alkaloid-based drugs through metabolic engineering Nat. Chem. Biol. 2017 13 249 258 10.1038/nchembio.2308 28199297
70. McDonald AD Perkins LJ Buller AR Facile in vitro biocatalytic production of diverse tryptamines Chembiochem 2019 20 1939 1944 10.1002/cbic.201900069 30864270
71. Menon N Richmond D Rahman MR Menon BRK Versatile and facile one-pot biosynthesis for amides and carboxylic acids in E. coli by engineering auxin pathways of plant microbiomes ACS Catal. 2022 12 2309 2319 10.1021/acscatal.1c04901
72. Sanna G Synthesis and biological evaluation of novel indole-derived thioureas Molecules 2018 23 2554 10.3390/molecules23102554 30301264
73. Ullrich R Poraj-Kobielska M Herold-Majumdar OM Vind J Hofrichter M Synthesis of indigo-dyes from indole derivatives by unspecific peroxygenases and their application for in-situ dyeing Catalysts 2021 11 1495 10.3390/catal11121495
74. El-Najjar N The chemical and biological activities of quinones: overview and implications in analytical detection Phytochem. Rev. 2011 10 353 10.1007/s11101-011-9209-1
75. Muneer A Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations Clin. Psychopharmacol. Neurosci. 2020 18 507 526 10.9758/cpn.2020.18.4.507 33124585
76. Chen Q Discovery of McbB, an enzyme catalyzing the β-carboline skeleton construction in the marinacarboline biosynthetic pathway Angew. Chem. Int. Ed. Engl. 2013 52 9980 9984 10.1002/anie.201303449 23913777
77. Aaghaz, S. et al. β-Carbolines as potential anticancer agents. Eur. J. Med. Chem. 216, 113321 (2021).
78. Szabó T Volk B Milen M Recent advances in the synthesis of β-carboline alkaloids Molecules 2021 26 663 10.3390/molecules26030663 33513936
79. Piechowska P Zawirska-Wojtasiak R Mildner-Szkudlarz S Bioactive β-carbolines in food: a review Nutrients 2019 11 814 10.3390/nu11040814 30978920
80. Singh M Vaishali Kumar R Singh V Catalyst-free and metal-free approach towards synthesis of amide- and thioamide-linked β-carboline-pyridine conjugates and estimation of their photophysical properties ChemistrySelect 2020 5 5172 5179 10.1002/slct.202001149
81. Huang H Antimalarial β-carboline and indolactam alkaloids from marinactinospora thermotolerans, a deep sea isolate J. Nat. Prod. 2011 74 2122 2127 10.1021/np200399t 21977916
82. Hou Y Pharmacodynamics assessment of β-carboline from the roots of Psammosilene tunicoides as analgesic compound J. Ethnopharmacol. 2022 291 115163 10.1016/j.jep.2022.115163 35247473
83. Benjdia A The thiostrepton A tryptophan methyltransferase TsrM catalyses a cob(II)alamin-dependent methyl transfer reaction Nat. Commun. 2015 6 8377 10.1038/ncomms9377 26456915
84. Pierre S Thiostrepton tryptophan methyltransferase expands the chemistry of radical SAM enzymes Nat. Chem. Biol. 2012 8 957 959 10.1038/nchembio.1091 23064318
85. Knox, H. L. et al. Structural basis for non-radical catalysis by TsrM, a radical SAM methylase. Nat. Chem. Biol.10.1038/s41589-020-00717-y (2021).
86. Wu, Y., Xu, R., Feng, Y. & Song, H. Rational design of a de novo enzyme cascade for scalable continuous production of antidepressant prodrugs. ACS Catal.10.1021/acscatal.2c00522 (2022)
87. Mori T Structural basis for β-carboline alkaloid production by the microbial homodimeric enzyme McbB Chem. Biol. 2015 22 898 906 10.1016/j.chembiol.2015.06.006 26120001
88. Wang X Developing E. coli-E. coli co-cultures to overcome barriers of heterologous tryptamine biosynthesis Metab. Eng. Commun. 2019 10 e00110 10.1016/j.mec.2019.e00110 31853442
89. Chen T Development and optimization of a microbial co-culture system for heterologous indigo biosynthesis Microb. Cell Fact. 2021 20 154 10.1186/s12934-021-01636-w 34348711
90. Serra-Moreno R Acosta S Hernalsteens JP Jofre J Muniesa M Use of the lambda Red recombinase system to produce recombinant prophages carrying antibiotic resistance genes BMC Mol. Biol. 2006 7 31 10.1186/1471-2199-7-31 16984631
91. Gibson DG Enzymatic assembly of DNA molecules up to several hundred kilobases Nat. Methods 2009 6 343 345 10.1038/nmeth.1318 19363495
92. Chaudhury S Lyskov S Gray JJ PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta Bioinformatics 2010 26 689 691 10.1093/bioinformatics/btq007 20061306
